Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Eyes Different Supply Routes for Non-Pfizer COVID-19 Vaccines: Kono
The Japanese government believes that it is necessary to consider different supply routes for COVID-19 vaccines that might be newly granted approval, apart from the current channel for Pfizer’s shots, vaccination campaign minister Taro Kono said on April 23. Since…
To read the full story
Related Article
- Vaccines for All People to Be Delivered to Local Govts by October-End: Kono
June 30, 2021
- 1st Vaccine Doses to Be Delivered for Half of Elderly by May: Kono
April 5, 2021
- Govt Plans Switch to 6-Dose Syringes for Elderly “Sometime in May”: Kono
March 29, 2021
- COVID-19 Vaccines to Be Shipped with 6-Dose Syringes from Week of April 12, for Use in 2nd-in-Line HCPs
March 23, 2021
- All Municipalities to Get 2nd Doses for HCPs by Week of May 10: Minister
March 15, 2021
- Japan Speeds Up Vaccine Delivery for HCPs, Kono Says All 2nd Doses to Reach Municipalities in 1st Half of May
March 8, 2021
- Govt to Deliver 1st COVID-19 Vaccine Dose for 3.7 Million HCPs in April: Minister
March 1, 2021
- Japan to Start Elderly Vaccine Rollout from April 12: Minister
February 25, 2021
- Up to 1.17 Million Vaccine Doses to Be Shipped for HCPs in First Half of March
February 22, 2021
REGULATORY
- Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
- GSK’s Exdensur, Lilly’s Inluriyo Missing from March Listing Roster
March 12, 2026
- Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
- Avelox Gains Coverage for MDR-TB via Public Knowledge Filing
March 12, 2026
- MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…